SFPIA
BLCM

Stevens First Principles Investment Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-50
Closed -$10K – 194
2015
Q4 		$10K Sell
50
-30
-38% -$5.37K 0.01% 156
2015
Q3 		$12K Buy
+80
New +$14.7K 0.01% 165

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stevens First Principles Investment Advisors's BLCM Position: Q1 2016 in Review

Stevens First Principles Investment Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2016, closing a stake of 50 shares — an estimated $10K sold.

Stevens First Principles Investment Advisors first reported a position in BLCM in Q3 2015 and held it in 2 quarters. The position peaked at $12K in Q3 2015. 78 funds tracked by Wall St. Rank hold BLCM as of Q1 2016.

  • Stevens First Principles Investment Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Stevens First Principles Investment Advisors sold 50 Bellicum Pharmaceuticals, Inc. shares in Q1 2016, an estimated $10K.
  • Stevens First Principles Investment Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2015 and held it in 2 quarters.
  • Stevens First Principles Investment Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $12K in Q3 2015.
  • 78 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2016.

Based on Stevens First Principles Investment Advisors's 13F filing for Q1 2016, filed 13 May 2016.